Lundbeck Files for U.S. Approval for Serdolect

COPENHAGEN, Sept 15 (Reuters) - Danish pharmaceutical group Lundbeck A/S said on Monday it had submitted a new drug application for its schizophrenia drug Serdolect to the U.S. Food and Drug Administration.